Biological validation that SF3b is a target of the antitumor macrolide pladienolide
Article first published online: 31 OCT 2011
© 2011 The Authors Journal compilation © 2011 FEBS
Volume 278, Issue 24, pages 4870–4880, December 2011
How to Cite
Yokoi, A., Kotake, Y., Takahashi, K., Kadowaki, T., Matsumoto, Y., Minoshima, Y., Sugi, N. H., Sagane, K., Hamaguchi, M., Iwata, M. and Mizui, Y. (2011), Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS Journal, 278: 4870–4880. doi: 10.1111/j.1742-4658.2011.08387.x
- Issue published online: 1 DEC 2011
- Article first published online: 31 OCT 2011
- Accepted manuscript online: 9 OCT 2011 11:45PM EST
- (Received 21 July 2011, revised 13 September 2011, accepted 26 September 2011)
Fig. S1. Antiproliferative action of E7107 against WiDr/WiDr-R and DLD1/DLD1-R cells.
Fig. S2. Pladienolide-resistant WiDr cells are established by transduction of pCLXIH-SF3B1 (R1074H) and pLenti/shSF3B1(4145).
Please note: As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer-reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
|FEBS_8387_sm_FigS1-S2.zip||121K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.